Brigitta Sackl came to biotechnology from the clinic floor rather than the laboratory. She trained as a dermal clinician and owned her own practice, which meant learning early what most of the industry learns late: that a technology proves its worth at the moment someone decides to use it on a patient, and that the decision is usually commercial before it is clinical.

She moved from practice into commercial work with global biotechnology, agricultural technology, aesthetics and wellness companies, where the job was less about the science than about the distance between a good product and a buyer who is allowed to buy it. That distance is longest in regulated markets, which is how she ended up in Saudi Arabia coordinating regulatory submissions in the SFDA context and building commercial routes into the Gulf.

Austrian by heritage and now dividing her time between Riyadh and Melbourne, she writes A7i's coverage of capital, companies and commercial structure. Her editorial focus is the path from what gets announced in the Gulf to what gets built, a question she has spent most of her career working through from the commercial side.

Expertise

  • Biotechnology commercialisation
  • In-vitro diagnostics
  • Agricultural technology
  • Aesthetics and wellness
  • Capital and company expansion in the Gulf
  • GCC market structure

Other professional roles

  • Director of Global Sales, Wallace Biotechnologies.

Elsewhere

LinkedIn

Articles